DiscoverEagle's Eye View: Your Weekly CV Update From ACC.org
Eagle's Eye View: Your Weekly CV Update From ACC.org
Claim Ownership

Eagle's Eye View: Your Weekly CV Update From ACC.org

Author: American College of Cardiology

Subscribed: 321Played: 12,055
Share

Description

The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
128 Episodes
Reverse
In this special edition of the View, Dr. Eagle looks at four studies presented at the recent TCT Conference that could have immediate effects on your practice. First, he discusses PROGRESS, that investigated how TAVR may be superior to clinical surveillance in patients with moderate aortic stenosis (AS) with at-risk features. He then examined SIMPLAAFY, that explored how the use of reduced-dose non-vitamin K oral anticoagulants (NOACs) was noninferior to dual antiplatelet therapy (DAPT) for a composite of adverse clinical outcomes through six months following left atrial appendage closure (LAAC). He then takes a look at SPYRAL AFFIRM, on the effectiveness of radiofrequency RDN on blood pressure (BP) at six months. Finally, Dr. Eagle offers a summary of a non-randomized analysis of the IRIS-MAIN registry that indicated no statistically significant difference in long-term all-cause mortality among Asian patients with unprotected left main coronary artery disease (CAD) who underwent PCI or CABG. Get ACC's full coverage of the TCT conference here. Subscribe to Eagle's Eye View  
In this week's View, Dr. Eagle looks at how black adults in disadvantaged neighborhoods are less likely to be diagnosed with atrial fibrillation (AFib).  He then examines the parameters used to detect mitral regurgitation and how they might be improved. He follows that with a look at how high coronary artery calcium scores (CAC) in young adults can signal higher 30-year mortality. Finally, Dr. Eagle offers a comparison of add-on treatments for resistant or uncontrolled hypertension (HTN). Subscribe to Eagle's Eye View  
In this week's View, Dr. Eagle looks at a brief report on how cardiac death remains a substantial contributor to on-duty mortality of U.S. firefighters, and how drivers of this trend may not be well identified by the current screening approaches.  He then examines a recent article in JACC Heart Failure on how heart failure with improved ejection fraction (HFimpEF) was associated with better outcomes than persistent heart failure with reduced ejection fraction (HFrEF) in both women and men. He follows that with a look at a metanalysis that compared dual antiplatelet therapy (DAPT) and direct oral anticoagulant (DOAC) monotherapy and their effects on device-related thrombosis (DRT) and major bleeding after left atrial appendage occlusion (LAAO). Finally, Dr. Eagle offers a summary of an analysis a recent study the reported modest increase in noninfarct-related artery (non-IRA) revascularization in patients with STEMI and multivessel coronary artery disease (CAD), with some caveats. Subscribe to Eagle's Eye View  
In this week's View, Dr. Eagle looks at the new ACC Scientific Statement on Exercise Prescriptions for Cardiovascular Health in Adults. He then examines a recent State-of-the-Art Review on the evolving role of multimodality cardiovascular imaging in the diagnosis and management of cardiac sarcoidosis (CS). He follows that with a look at a risk stratification model based on cardiac magnetic resonance (CMR) results. Finally, Dr. Eagle offers a summary of an analysis of the PREVENT trial on how preventive PCI lowers CV risk in patients with lipid-rich plaques. Subscribe to Eagle's Eye View  
In this week's View, Dr. Eagle looks at continued sex disparities in CV clinical trials. He then examines how preemptive left stellate ganglion block (SGB) is associated with a reduced incidence of postoperative atrial fibrillation (POAF) in patients undergoing CABG. He follows that with a look at bifurcation lesions as analyzed in the OCTOBER Trial. Finally, Dr. Eagle offers a brief vignette on resistant hypertension and how to manage it.
loading
Comments